

The Drug & Device Development Co., Inc

[View the current The Drug & Device Development Co., Inc Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/22139-The+Drug+%26+Device+Development+Co.%2C+Inc.html)

(<http://www.bioportfolio.com/bi corporate/22139-The+Drug+%26+Device+Development+Co.%2C+Inc.html>)

Contact Details:

P.O. Box 3515

Redmond

Washington

98073-3515

United States of America

Tel: (425) 861-8262

Fax: 425) 869-5854

Email: ddd@druganddevice.com

The Drug & Device Development Co., Inc. founded in 1985, has expertise in the regulatory, clinical, quality and statistical aspects of drug, biologic, diagnostic, and medical device development. The DDD group consists of both full-time and part-time specialists. Each one is well experienced in one or more aspects of the drug, biologic and/or device approval process. The major focus of DDD's services is related to product approval support. Services include the following: regulatory and clinical strategies and implementation for pre-market submissions, pre-clinical and clinical study design, protocols, monitoring, clinical auditing, data entry, database management, statistical analysis and evaluation, report writing and training. DDD assists companies in setting up Design Controls, ISO and GMP compliance programs.

Recent Publications by The Drug & Device Development Co., Inc:



- [Stereoselective protein binding of tetrahydropalmatine enantiomers in human plasma, HSA, and AGP, but not in rat plasma.](#)

Tetrahydropalmatine (THP) is one of the active alkaloid ingredients of... 21st November, 2009

Department of Pharmaceutical Analysis and Drug Metabolism, College of- Chirality. 2009 Nov 19. ([DOI](#) [Direct Link](#))

- [Immunoabsorption apheresis and immunosuppressive drug therapy in the treatment of complicated HCV-related cryoglobulinemia.](#)

The immunosuppressive drug therapy (IDT) is not always effective to avoid... 21st November, 2009

Department of Clinical and Medical Therapy, Plasmapheresis Unit,- J Clin Apher. 2009 Nov 19. ([DOI](#) [Direct Link](#))

- [Release and activity of anti-TNFalpha therapeutics from injectable chitosan preparations for local drug delivery.](#)

The immunosuppressive drug therapy (IDT) is not always effective to avoid... 21st November, 2009

Department of Biomedical Engineering, Duke University, Durham, North- J Biomed Mater Res B Appl Biomater. 2009 Nov 19. ([DOI Direct Link](#))

- [Facile synthesis of functional polyperoxides by radical alternating copolymerization of 1,3-dienes with oxygen.](#)
We have developed a facile synthesis of degradable polyperoxides by the... 21st November, 2009
Department of Applied Chemistry and Bioengineering, Graduate School of- Chem Rec. 2009 Nov 19. ([DOI Direct Link](#))
- [Resistance of stem-like cells from neuroblastoma cell lines to commonly used chemotherapeutic agents.](#)
BACKGROUND: Cancer stem cell theory suggests that the presence of tumor... 21st November, 2009
The Carman and Ann Adams Department of Pediatrics, Children's Research- Pediatr Blood Cancer. 2009 Nov 19. ([DOI Direct Link](#))
- [The novel ruthenium-gamma-linolenic complex \[Ru\(2\)\(aGLA\)\(4\)Cl\] inhibits C6 rat glioma cell proliferation and induces changes in mitochondrial membrane potential, increased reactive oxygen species generation and apoptosis in vitro.](#)
The present study reports the synthesis of a novel compound with the... 21st November, 2009
Department of Fundamental Chemistry, University of Sao Paulo, Sao Paulo,- Cell Biochem Funct. 2009 Nov 19. ([DOI Direct Link](#))
- [Antiepileptic drugs in the control of the impulses disorders.](#)
The disorders classified as control of the impulses; explosive... 21st November, 2009
- Actas Esp Psiquiatr. 2009 Jul;37(4):205-212.
- [Agomelatine: A novel pharmacological approach to treating depression.](#)
Agomelatine is a melatonin analogue which represents a novel class of... 21st November, 2009
Medical Information Department, Prous Science, Barcelona, Spain.- Drugs Today (Barc). 2009 Aug;45(8):599-608. ([DOI Direct Link](#))
- [Besifloxacin ophthalmic suspension for bacterial conjunctivitis.](#)
Besifloxacin hydrochloride ophthalmic suspension 0.6 (Besivance) is a... 21st November, 2009
Bertino Consulting, Schenectady, New York, USA.- Drugs Today (Barc). 2009 Aug;45(8):577-588. ([DOI Direct Link](#))
- [NMDA receptor antagonist MK-801 reduces neuronal damage and preserves learning and memory in a rat model of traumatic brain injury.](#)
Objective NMDA receptor channel plays an important role in the... 21st November, 2009
Medical College of Shanghai Jiaotong University, Shanghai 200025, China;- Neurosci Bull. 2009 Dec;25(6):367-375.
- [Independent Association of Drug-Resistant Hypertension to Reduced Sleep Duration and Efficiency.](#)
BackgroundExperimentally induced sleep deprivation can raise blood... 21st November, 2009
[1] Prosserman Centre for Health Research, Samuel Lunenfeld Research- Am J Hypertens. 2009 Nov 19. ([DOI Direct Link](#))
- [The Role of Advice in Medication Administration Errors in the Pediatric Ambulatory Setting.](#)
BACKGROUND:: In the pediatric setting, adverse events occurring at the... 21st November, 2009
From the *Harkness-Health Foundation Fellow, Division of General Internal- J Patient Saf. 2009 Sep;5(3):168-175. ([DOI Direct Link](#))
- [Monitoring Pregnant Women's Illicit Opiate and Cocaine Use With Sweat Testing.](#)
Dependence on illicit drugs during pregnancy is a major public health... 21st November, 2009
From the *INSERM UMR 927, Universite de Poitiers, Faculte de Medecine et- Ther Drug Monit. 2009 Nov 18. ([DOI Direct Link](#))
- [A Novel HPLC Method for Quantification of 10 Antiepileptic Drugs or Metabolites in Serum/Plasma Using a Monolithic Column.](#)
Therapeutic drug monitoring of antiepileptic drugs (AEDs) is important in... 21st November, 2009
From the Department of Clinical Pathology, Cleveland Clinic, Cleveland,- Ther Drug Monit. 2009 Nov 18. ([DOI Direct Link](#))
- [Doxorubicin in Lymphoma: Association Between Pharmacokinetic Variability and Clinical Response.](#)
Despite many years of clinical use in Hodgkin lymphoma, no previous... 21st November, 2009

Press Releases on The Drug & Device Development Co., Inc:

STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe	27th November, 2009		PARIS, November 27 /PRNewswire/ -- Stallergenes has been granted European approval to market Oralair(R) in both adults and children through a Mutual Recognition Procedure. Germany, the first country
FDA's Woodcock Discusses Pain Management and Drug Safety in Nov. 26, 2009 Issue of The New England Journal of Medicine	25th November, 2009	U.S. Food and Drug Administration	SILVER SPRING, Md., Nov. 25 /PRNewswire-USNewswire/ -- An article by Janet Woodcock, M.D., director of the FDA's Center for Drug Evaluation and Research, titled "A Difficult Balance - Pain
Onyx Pharmaceuticals Announces December 2009 Investor Events	25th November, 2009	Onyx Pharmaceuticals, Inc.	EMERYVILLE, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the company will host two investor events in December: ASH Briefing December 7,
U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine)	25th November, 2009	Tibotec Therapeutics	- Severe, potentially life-threatening, and fatal skin reactions have been reported in patients taking INTELENCE. These include cases of Stevens-Johnson syndrome, toxic
Phonak Successfully Hosts Hearing Care for Adults 2009 Conference	25th November, 2009	Phonak	CHICAGO and STAFFA, Switzerland, Nov. 25 /PRNewswire/ -- From November 16-18, Phonak, the leading manufacturer of innovative hearing solutions, presented the second edition of the Hearing Care for

BioNews Results for The Drug & Device Development Co., Inc



- [DCGI keen to adapt Gujarat FDCA's e-governance model for CDSCO](#)
PharmaBiz: Nov 23 2009 2:54AM Matching: drug
- [Drug Delivery Partnerships \(DDP\)](#)
Pharmalicensing: Nov 22 2009 12:26PM Matching: drug
- [FDA Says Heartburn Drugs Can Interfere with Plavix](#)
Drugs.com: Nov 21 2009 11:55PM Matching: drug
- [FDA says heartburn drugs can interfere with Plavix](#)
KTRK TV: Nov 22 2009 3:41AM Matching: drug
- [ICT Fails To Accelerate Drug Approvals](#)
MediLexicon: Nov 21 2009 1:45PM Matching: drug
- [Medical News: ICT Fails To Accelerate Drug Approvals](#)
BioFind: Nov 21 2009 1:02PM Matching: drug
- [ICT Fails To Accelerate Drug Approvals](#)
Medical News Today: Nov 21 2009 9:06AM Matching: drug
- [Poniard Drug A Possible Colorectal Cancer Treatment](#)
Drug Discovery and Development: Nov 21 2009 9:58AM Matching: drug
- [UPDATE: FDA Reviewing Safety Of Weight-Loss Drug Meridia](#)
Nasdaq: Nov 21 2009 12:46AM Matching: drug
- [Popular Heartburn Meds Interfere With Plavix](#)
Drug Discovery and Development: Nov 21 2009 9:59AM Matching: drug

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

